NIBAN2

Across TCGA pan-cancer cohorts, NIBAN2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NIBAN2 data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher NIBAN2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NIBAN2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, GBM, and PDAC are the cancer types where NIBAN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.956	0.757	.002	53	view →
GBM	OS	Quartile	All	0.671	0.897	.001	22	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	7	view →
LUAD	OS	Median	II,III,IV	1.000	0.862	.004	6	view →
UCEC	DFS	Median	II,III,IV	0.865	0.532	.029	4	view →
LSCC	OS	Tertile	All	0.816	1.000	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NIBAN2–HNSC (OS)

Open the HNSC breakdown →